# US 2005/0239741 A1 · Novel synthetic ganglioside derivatives and compositions thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0239741 A1
- Document ID: US20050239741A1
- Status: Published application
- Kind: A1
- Application number: 10/487,841
- Filed: 2002-08-29
- Published: 2005-10-27
- Earliest claimed: 2001-08-29
- Assignees: Seneb Biosciences, Inc.
- Inventors: Shawn Defrees; Zhi Wang
- Web page: https://patentgrep.com/patent/US20050239741A1

## CPC

- C12P 19/28: N-glycosides
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07H 3/06: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- C07H 17/02: Heterocyclic radicals containing only nitrogen as ring hetero atoms
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

Novel synthetic gangliosides and pharmaceutical compositions containing such synthetic gangliosides are described. Methods of making the novel synthetic ganglioside compounds and compositions as well as their use in the field of neuroprotection and cancer treatment is also described.

## Claims

### Claim 1

A compound having the formula:
wherein
Z is a member selected from O, S, C(R2)2 and NR2;
X is a member selected from H, —OR3, —NR3R4, —SR3, and —CHR3R4;
R1, R2 and R3 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, —C(═M)R5, —C(═M)-Z-R5, —SO2R5, and —SO3;
wherein
M and Z are members independently selected from O, NR6 or S; and
Y is a member selected from H, —OR7, —SR7, —NR7R8, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heterocycloalkyl
wherein
R5, R6, R7 and R8 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl.

### Claim 2 (depends on 1)

The compound according to claim 1, with the proviso that when X is NHR4, in which R4 is a member selected from H and —C(═O)R5, in which R5 is substituted or unsubstituted alkyl; Y is OH; and Z is O, R5 is other than a member selected from substituted or unsubstituted alkyl.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein R1 has the formula:
in which
R9, R10, R11, R12 and R13 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl substituted or unsubstituted heterocycloalkyl, NR14R15, OR14, —CN, and —C(═L)R14
wherein
L is a member selected from O, S, and NR16;
R14 and R15 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, C(O)R17, OR17, SR17 and NR17R18
wherein
R16, R17 and R18 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, and wherein
a member selected from R9 and R10; R9 and R11; R9 and R12; R9 and R13; R10 and R11; R10 and R12; R10 and R13; R11 and R12; R11 and R13; and R12 and R13, together with the atom to which they are attached, are optionally joined to form a ring, wherein said ring is a member selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroalkyl.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein R1 has the formula:
wherein
R11, R12 and R13 are members independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, NR14R15, OR14, —CN, —C(═L)R14
wherein
L is a member selected from O, S, and NR16;
R14 and R15 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, C(O)R17, OR17 and NR17R18
wherein
R16, R17 and R18 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, and wherein
a member selected from R11 and R12; R11 and R13; and R12 and R13, together with the atom to which they are attached, are optionally joined to form a ring, wherein said ring is a member selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroalkyl.

### Claim 5 (depends on 1)

A compound according to claim 1, wherein R1 has the formula:
R9, R10, R11, R13, R19, R20 and R21 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, NR14R15, OR14, —CN, and —C(═L)R14
wherein
L is a member selected from O, S, and NR16;
R14 and R15 are members independently selected from H substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, C(O)R17, OR17, SR17 and NR17R18
wherein
R16, R17 and R18 are members independently selected from H, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocycloalkyl, and wherein
a member selected from R9 and R10; R9 and R11; R9 and R13; R9 and R21; R9 and R19; R9 and R20; R9 and R21; R10 and R11; R10 and R13; R10 and R19; R10 and R20; R10 and R21; R11 and R13; R11 and R19; R11 and R20; R11 and R21; and R13 and R19; R13 and R20; R13 and R21; R19 and R20; R19 and R21; and R20 and R21 together with the atom to which they are attached, are optionally joined to form a ring, wherein said ring is a member selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted heteroalkyl.

### Claim 6 (depends on 3)

The compound according to claim 3, wherein R5 is CH3.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein the saccharide has a formula that is selected from the group consisting of:

### Claim 8 (depends on 7)

The compound according to claim 7, wherein the saccharide is deacetylated.

### Claim 9 (depends on 1)

The compound according to claim 1, having the formula:

### Claim 10 (depends on 1)

The compound according to claim 1, having the formula:

### Claim 11 (depends on 1)

The compound according to claim 1, having the formula:

### Claim 12 (depends on 1)

The compound according to claim 1, having the formula:

### Claim 13 (depends on 1)

The compound according to claim 1, having the formula:

### Claim 14 (depends on 1)

The compound according to claim 1, having the formula:

### Claim 15 (depends on 1)

The compound according to claim 1, having the formula:

### Claim 16 (depends on 1)

The compound according to claim 1, having the formula:

### Claim 17 (depends on 1)

The compound according to claim 1, having the formula:

### Claim 18 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 1)

A method for the prevention or treatment of a disorder of the nervous system in an animal or human comprising the step of administering to an animal or human in need thereof a therapeutically effective amount of the compound of claim 1.

### Claim 20 (depends on 19)

The method of claim 19, wherein said disorder of the nervous system is selected from the group consisting of Parkinson's disease, ischemia, stroke, Alzheimer's disease, depression, anxiety, encephalitis, meningitis, amyotrophic lateral sclerosis, trauma, spinal cord injury, nerve injury, and nerve regeneration.

### Claim 21 (depends on 1)

A method for the treatment of a glioma in a human comprising the step of administering to the human in need thereof a therapeutically effective amount of the compound claim 1.

### Claim 22 (depends on 1)

A method of synthesizing a synthetic ganglioside compound of claim 1, wherein the steps of synthesis of the saccharide moiety comprise:
contacting an acceptor molecule comprising a sphingoid moiety and a glucose (Glc) with a galactosyltransferase enzyme and a galactose (Gal) donor molecule to form:
contacting the
with a trans-sialidase enzyme and a sialic acid (NANA) donor molecule to form:
contacting the
with a N-acetyl galactose (GalNAc)-transferase enzyme and a GalNAc donor molecule to form:
contacting the
with a galactosyltransferase enzyme and a galactose (Gal) donor molecule to form
contacting the
with a fatty acid moiety under conditions sufficient to form a ganglioside.
